Abstract: The present invention relates to novel manganese complexes and their use, inter alia, for homogeneous catalysis in (1) the preparation of imine by dehydrogenative coupling of an alcohol and amine; (2) C—C coupling in Michael addition reaction using nitriles as Michael donors; (3) dehydrogenative coupling of alcohols to give esters and hydrogen gas (4) hydrogenation of esters to form alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones), or polyesters); (5) hydrogenation of amides (including cyclic dipeptides, lactams, diamide, polypeptides and polyamides) to alcohols and amines (or diamine); (6) hydrogenation of organic carbonates (including polycarbonates) to alcohols or hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (7) dehydrogenation of secondary alcohols to ketones; (8) amidation of esters (i.e.

Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.

Abstract: The present invention relates to compositions and methods comprising cell surface markers for pluripotent-derived cells, in particular, pancreatic endoderm-type cells, derived from pluripotent stem cells.

Abstract: A method for recovery of gold from gold-containing materials, such as electronic waste material, minerals and sands is described. The method includes crushing the gold containing material to obtain a particulate material. The particulate material is then preheated in an oxygen-containing gas environment in a preheating zone. The method also includes mixing the oxidized particulate material with a chlorine-containing material and treating the mixture in a reaction zone. The treatment is carried out by heating the mixture to provide thermal decomposition of the chlorine-containing material and produce a chlorine-containing gas mixture, and by applying an electromagnetic field to the chlorine-containing gas mixture to provide ionization of chlorine. A volatile gold-containing chloride product, produced in the reaction zone as a result of a chemical reaction between gold and chlorine ions, is then cooled to convert the volatile gold-containing chloride product into solid phase gold-containing materials.

Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR ? chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR ? chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.

Abstract: This invention is directed to a method of oxygenating hydrocarbons with molecular oxygen, O2, as oxidant under electrochemical reducing conditions, using polyoxometalate compounds containing copper such as Q10[Cu4(H2O)2(B-?-PW9O34)2] or Q13{[Cu(H2O)]3[(A-?-PW9O34)2(NO3)?]} or solvates thereof as catalysts, wherein Q are each independently selected from alkali metal cations, alkaline earth metal cations, transition metal cations, NH4+, H+ or any combination thereof.

Abstract: A hybrid supercapacitor where the charging state is indicated by color is demonstrated. The device comprises a molecular network that functions as both the battery-type electrode and the charge indicator. Related batteries, electrodes and devices, their processes of preparation and methods of use are provided as well. Further included in this invention are data-storage devices and catalysts based on multilayers comprising metal-ion organic complexes. This invention further provides methods of preparation of the multilayers, of the data-storage devices, of the catalyst devices and methods of use thereof.

Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.

Abstract: Provided herein is a family of programmable de novo designed transmembranal protein domain polypeptides, and uses thereof in the production of engineered chimeric antigen receptor T (CAR T) cells, which are used, for example, to fight cancer.

Abstract: A method of treating cancer in a subject is disclosed. The method comprises: (a) analyzing for the abundance of at least one bacteria in the tumor microbiome of the subject; and (b) administering to the subject a therapeutically effective amount of an immunotherapy treatment on the basis of the abundance of said at least one bacteria.

Abstract: A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises: a) at least one bilayer-forming lipid; b) a polymeric compound having the general formula I: wherein m, n, L, X, Y, and Z are as defined herein; and c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.

Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.

Abstract: The present invention relates to compositions and methods comprising cell surface markers for pluripotent-derived cells, in particular, pancreatic endoderm-type cells, derived from pluripotent stem cells.

Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract: A method of assessing odors, comprises providing an electronic nose that extracts measurements from odors, from which measurements at least n chemical descriptors are extracted where n is greater than unity, and typically around 18. The electronic nose is applied to an odor, and odor information is extracted. The information is plotted to a first location on an n-dimensional sample space, each dimension being related to a respective one of the n chemical descriptors or otherwise optimized for the particular enose and the measurements it makes; and an assessment of the odor is provided based on the plotted location. The assessment may be a description based on odor describing terms, or may be a chemical description in terms of chemicals that can synthesize the odor, and the odor may then be synthesized based on the chemical description.

Abstract: A method of treating an ischemic heart disease in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of Agrin in an anterograde intracoronary manner, thereby treating the ischemic heart disease in the subject.

Abstract: A method of assessing a subject including: measuring a plurality of respirations of the subject; determining one or more respiration parameter from the plurality of respirations; and determining, using the one or more respiration parameter, one or more of: a state of consciousness of the subject; and a prognosis of the subject.

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Abstract: A genetically modified human beta-glucocerebrosidase (GCase) is disclosed. The genetically modified GCase comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2; and comprising mutations at coordinates L34P, K224N/G, T369E and N370D, where the coordinates correspond to said SEQ ID NO: 2; and capable of catalyzing hydrolysis of a glycolipid glucosylceramide (GlcCer). Pharmaceutical compositions comprising the genetically modified GCase and therapeutic methods of using same are also disclosed.